BaCKGRoUND
In Spain, increased cases of listeriosis were recorded between 2008 and 2014, with up to 1.15 cases per 100,000 inhabitants according to the last European summary report in 2014, signifying one of the highest incidences of listeriosis in Europe (1) (2) (3) (4) . Over this period, outbreaks were additionally documented in Austria, Portugal, Spain, and Denmark (1, (5) (6) (7) (8) . Listeriosis has only recently been listed as a notifiable disease in Spain since March 2015 (9) , and therefore, the annual incidence may be even higher (1-5, 10, 11) . Reduced immunocompetency of listeriosis patients was recently reported as a major risk factor for fatal outcomes (12) . Epidemiologically specific Listeria monocytogenes genotypes show greater virulence, contributing to more human listeriosis cases (13, 14) . Despite accumulating epidemiological data on listeriosis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , effective immunological biomarkers are yet to be established that a priori appear to represent valuable tools to prepare clinical vaccines for patients at high risk of listeriosis, which may help to reduce the incidence of infectious disease.
The main purpose of this study was to establish the annual incidence of listeriosis in two northern Spain communities with voluntary reports of high numbers of listeriosis cases. We Table 2 ). In agreement with data obtained from the detailed investigation performed in France (14) , CC1 and CC4 hypervirulent clones corresponded to listeriosis cases of meningitis or materno-fetal transmission. We additionally detected another hypervirulent clone, ST6 (CC6), isolated from a patient with squamous cell glottis carcinoma (Tables 1 and 2, 2014-2015) . The data collectively suggest that bacterial isolates of our listeriosis patients have a highly virulent phenotype.
In Vitro and In Vivo Replication of Clinical L. monocytogenes Isolates than two standardized L. monocytogenes controls (14, 17, 20, 23) . The highest invasive L. monocytogenes virulence corresponded to that in deceased patients ( †, Figure 1A , left plot). We additionally examined in vivo virulence using standard procedures to measure the number of viable bacteria (CFU) that reached the spleens in C57BL/6 mice, a mice model highly resistant to listeriosis (20, 21, 23) . Inoculation of mice with bacterial isolates from listeriosis patients with tumors, including those of deceased patients, induced 1000-fold higher levels of viable bacteria (CFU) in spleen, relative to those inoculated with isolates from the remaining listeriosis patients or either of the two standards, suggestive of very high virulence (right plot, Figure 1A) . The similar in vitro and in vivo data suggest that measurement of listeriosis virulence in MoDC could provide a valid, low-cost, and rapid method without the necessity of inoculating mice. MLST genotyping of these highly virulent clinical isolates of listeriosis patients with tumors under active chemotherapeutic treatment [ST37 (CC37), ST219 (CC4), ST213 (CC213), ST6 (CC6), ST87 (CC87), and ST26 (CC26)] revealed the presence of at least two hypervirulent complex clones previously reported in France, CC4 and CC6 (14) , which, in our study, corresponded to those in tumor patients subjected to chemotherapeutic regimens of cisplatin-etoposide (CC4) and cetuximab (CC6) (Tables 1  and 2 ). The genotype of the 2014 outbreak strain in northern Spain, ST87 (CC87), was isolated from a listeriosis patient with tumors subjected to chemotherapy with cisplatin-etoposide, confirming our previous suggestion that CC87 is a hypervirulent complex clone (5) . Two other strains of particular interest were ST37 (CC37) and ST213 (CC213), isolated these strains from deceased patients with tumors under chemotherapy treatment with cisplatin and taxocel. These strains displayed the highest virulence and emerged as novel hypervirulent strains associated with listeriosis patients containing tumors. We concluded that patients with tumors treated with chemotherapy present a highrisk factor for invasive L. monocytogenes infection, consistent with earlier reports (12) , since this patient population is highly sensitive to previously reported hypervirulent strains, such as CC4, CC6 (17), or CC87 (5), and newly emerging hypervirulent complex clones, CC37 or CC213, that may cause fatal outcomes (this study). (28) . Second, the levels of antibodies against the L. monocytogenes GAPDH virulence factor epitope, GAPDH1-22, are relevant biomarkers. Anti-GAPDH1-22 antibody titers reflect the ability of GAPDH to confer listeriosis protection (20, 21, 29, 30) . Blood tests of listeriosis patients reflected the expected parameters: low lymphocyte numbers (3%-6%), normal monocyte values (2%-13%) ( Table 3 , blood test columns), and high neutrophil counts in several patients (≥ 75%-94.9%), with immature granulocytes in certain patients (28.5%), and especially high numbers in the two deceased patients. Patients with tumors, in particular deceased patients, presented very low IL-17A/IL-6 ratios and high levels of IL-6 and IL-10 in sera, while IFN-γ levels were similar as controls ( Table 3 , 2014-2015; Figure 1B) . However, listeriosis patients with autoimmune diseases or miscarriages showed high levels of IL-17A/IL-6 ratios (Table S1 in Supplementary Material). These results indicate that impairment of the Th17/Th2 balance toward Th2 responses may present a risk factor leading to fatal outcomes. High levels of IgG antibodies (OD ≥ 2.0) against the bacterial epitope, GAPDH1-22 (20, 21) , were detected in listeriosis patients with miscarriages, autoimmune diseases, or kidney transplants (OD of 2.5-4.5 OD) (Table S1 in Supplementary Material). The majority of listeriosis patients containing tumors had low IgG anti-GAPDH1-22 levels (OD of 0.2-0.8), presenting the deceased patients basal levels (0.02-0.05 OD) ( Table 3 , anti-GAPDH1-22 column). Anti-listeriolysin O (LLO) antibodies were detected at extremely low levels in all listeriosis patients (≤0.15 OD), eliminating the possibility of using LLO antibodies as biomarkers (data not shown). Accordingly, we conclude that low levels of anti-GAPDH1-22 antibodies, together with low IL-17A levels, are two valid immunological biomarkers of poor prognosis in listeriosis patients with tumors under chemotherapeutic treatment.
Next, we selected representative listeriosis patients between 2012 and 2014 from our institutional biobanks containing stores of bacterial isolates and cells to establish the epidemiological and immunological parameters of interest. In total, 81 cases of listeriosis between 2012 and 2014 occurred, including 16 deaths, 9 with tumors, 2 autoimmune diseases, 1 cirrhosis, 2 fetuses (miscarriages), and 1 child (stillbirth). Our selection of listeriosis patients was based on those representative of the most prevalent clinical manifestations in our institutions, specifically, those with tumors, autoimmune disease, miscarriages, and renal or hepatic transplants (5, 4, 11) . Consequently, we selected three listeriosis patients with tumors, squamous cell glottis carcinoma treated with cisplatin, hepatocellular carcinoma treated with microwave ablation, and cutaneous primary lymphoma of giant cells subjected to rituximab treatment; three listeriosis patients with autoimmune diseases, an autoimmune hyperthyroidism treated with tirodril, arteritis of giant cells, and a Guillain-Barre syndrome treated with prednisone, two listeriosis-associated miscarriages in pregnant women, and one listeriosis patient with cirrhosis and hepatic transplant treated with several immune-suppressors (prednisone, mycophenolate mofetil, and tacrolimus) ( Table 1 , selection in 2012-2014 rows). We confirmed the isolation of highly virulent clinical isolates as CC1, CC3, and CC4 from listeriosis patients with tumors subjected to chemotherapy. Verification of virulence in vitro using MoDC or in vivo revealed 1000-fold higher RI values and CFU than the standard bacteria ( Table 2 , selection in 2012-2014 rows; Figure 1A , asterisks under selection 2012-2014). Second, we detected in the listeriosis patients with cancer, low levels of IL-17A (bars with asterisk in Figure 1B ; Table 3 , selection in 2012-2014 rows) and anti-GAPDH1-22 antibody levels (anti-GAPDH1-22 column in Table 3 , selection 2012-2014). All other listeriosis groups of patients (autoimmune, hepatic transplanted, or miscarriages) presented bacterial isolates with virulence similar to standard strains ( Figure 1A , selection 2012-2014) as well as high IL-17A and IgG anti-GAPDH1-22 levels ( Table 3; Table S1 in Supplementary Material, selection 2012-2014).
Since the main risk factors in our listeriosis patients with tumors subjected to chemotherapeutic treatments were identified as reduced Th17 immunocompetency, we hypothesized that this biomarker parameter could be improved in activated MoDC. We based our hypothesis in the ability of DC to elicit pro-inflammatory Th1/Th17 and effective B cell-CD4 + T cell immune responses (21, 26, 27) , even in clinical trials for patients with cancer (31) . For this purpose, we activated MoDC from all listeriosis patients with cancer vaccine with GAPDH1-22 peptide as described (20, 21) and observed in all MoDC an activated phenotype, CD45
+ MHC-II + CD86 + CD14 − , similar to activated MoDC from controls (19) (20) (21) (Figure 2A) . We also observed that GAPDH1-22-activated MoDC from listeriosis patients with cancer released high levels of TNF-α while low levels of IL-6 and IL-10 ( Figure 2B) , suggesting a shifting toward Th1 pattern. Finally, we have not addressed here the type of food associated with our listeriosis patients but in all cases, listeriosis infection was related to consumption of contaminated food as reported in other epidemiological studies (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) 17) .
DIsCUssIoN
Epidemiological studies of European outbreaks and case studies, coordinating clinical data and bacteriological genotyping, have led to significant progress in listeriosis surveillance and recently revealed the presence of hypervirulent strains in clinical isolates (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (16) (17) (18) as well as reduced immunocompetency as a main risk factor (12) . Our data on listeriosis cases collected from two northern Spain communities, Gipuzkoa and Cantabria, over the course of a year (obtained to calculate annual listeriosis incidences) were in agreement with these findings. Our study concludes that the most important risk factors for listeriosis are the reduced Th17 immune competency of patients with cancer associated with the chemotherapy received and their high sensitivity to infection with hypervirulent strains, along with low levels of two immunological biomarkers, IL-17A/IL-6 ratios, and IgG anti-GAPDH1-22 antibodies.
First, fatal outcomes were only observed in listeriosis patients with cancer receiving chemotherapy and not in autoimmune or renal-hepatic transplanted patients receiving immunesuppressants or in the elderly, arguing low Th17 immune abilities caused by chemotherapy were risk factors more important than immune-senescence or autoimmunity.
Second, we presented a simple and rapid method to examine virulence in resting MoDC that revealed a correlation of L. monocytogenes hypervirulent strains with mortality in listeriosis patients with tumors receiving chemotherapy. In particular, these patients display high sensitivity not only to infections with hypervirulent invasive L. monocytogenes strains associated with meningitis, such as CC1, CC4, or CC6 (14) and other hypervirulent bacterial strains prevalent in northern Spain communities, such as CC87 (5, 10) , but also to newly reported hypervirulent invasive L. monocytogenes strains, such as CC37, CC26, and CC213, isolated from deceased patients (this study). Third, two biomarkers in the sera of patients with poor listeriosis prognosis were distinguished: (i) low IL-17A/IL-6 ratios that reflected a shift in the immune balance toward Th2 anti-inflammatory responses and (ii) low production of anti-GAPDH1-22 antibodies that suggested reduced CD4 + T cell-B cell responses. Dysfunction of Th17 immune responses in listeriosis patients with tumors under chemotherapeutic treatment appears to explain the high bacterial loads and reduced production of antibodies (24, 28) , as IgG anti-GAPDH1-22 antibodies. Listeriosis patients with other co-morbidities presented better Th17 and CD4 + T cell immune responses. High levels of IL-6 were also reported in bacterial meningitis of children and experimental listeriosis (32, 33) , suggesting this cytokine plays a relevant role. Moreover, IL-10 high levels were also reported to increase in listeriosis of aged mice with high bacterial loads (28) . Therefore, high levels of Th2 cytokines (IL-6 or IL-10) seemed related with severe listeriosis.
Vaccinations are best measures to prevent opportunistic infections, such as invasive L. monocytogenes. In this regard, DC or synthetic vaccines containing GADPH1-22 epitopes and targeted to DC seemed to confer protection against experimental listeriosis, promoting Th1-Th17 and CD4
+ -CD8
+ T cell immune responses (20, 21, 30, 34) . Here, we report that GAPDH1-22 epitopes can activate MoDC of listeriosis patients with cancer receiving chemotherapy to release high levels TNF-α while low production of IL-6 and IL-10, a clear Th1 cytokine pattern. These findings should contribute toward meeting the urgent need to develop clinical MoDC vaccines for improving Th17 immune competency in listeriosis patients with cancer.
CoNCLUsIoN
Listeriosis is a serious infection that causes mortality especially in fetuses and elderly patients with tumors under chemotherapeutic treatment. Examined annual incidences of listeriosis in Gipuzkoa and Cantabria indicated 1.86 and 1.71 cases per 100,000 inhabitants. Considering the reduced Th17 immunocompetency as the main risk factor of listeriosis, biomarkers of poor prognosis, such as high sensitivity to hypervirulent Listeria clones, low IL-17A/IL-6 ratios, and anti-GAPDH1-22 antibodies should assist in reducing listeriosis incidence. They can also contribute to listeriosis epidemiology and select vaccine antigens and vectors that improve innate and specific immune abilities of patients at high risk of listeriosis.
statistics
For all laboratory analyses, in vitro and in vivo virulence assays, blood tests and antibodies assays via ELISA, a Student's t-test was applied. All analyses were performed in triplicate, and results expressed as the mean ± SD calculated. P ≤ 0.05 was considered significant. The GraphPad software was used for graph generation. ANOVA was applied for cytokine measurements according to the manufacturer's instructions. aUtHoR CoNtRIBUtIoNs CA-D, planned, directed the study, performed the meetings with all participants to arrange the performance of the study and acted as a corresponding author. ORCID code: 0000-0002-4585-6959. RC-G, performed the study and collected all samples from both Hospitals. HT-N helped with the performance of the study. JM collected the listeriosis samples from patients: bacteria
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